FEATURED ARTICLES
4 Steps To Make A Business Case For Digital Endpoints
Anita Burrell explains how to build a business case for including digital endpoints and the elements to consider.
-
![Number 3-GettyImages-2231293069]( "3 Quick Takes From A PI With 100+ Trials To His Name")
3 Quick Takes From A PI With 100+ Trials To His NamePrincipal investigator Norman B. Gaylis, MD, shares his perspective on patient recruitment, protocol design, and vendor selection.
-
![Mental Health, memory problems-GettyImages-1367838230]( "Alzheimer's Trial Targeting Amyloid Beta Oligomers Sees Cost Savings, Patient Satisfaction With New Screening")
Alzheimer's Trial Targeting Amyloid Beta Oligomers Sees Cost Savings, Patient Satisfaction With New ScreeningAcumen Pharmaceuticals' Eric Siemers, MD, discusses their novel Alzheimer's disease screening method and trial design for investigational drug sabirnetug that keeps both the clinical site and patient experience in mind.
-
![Megan and Tina_450x300]( "Why More Biotechs Are Starting Trials In Australia")
Why More Biotechs Are Starting Trials In AustraliaWhy are so many U.S. biotechs heading to Australia for their first-in-human trials? Speed, cost, and simplicity. In our latest piece, Megan Robertson and Tina Soulis break down how sponsors can move from protocol to first patient in just a few months—while saving money and generating data regulators will accept worldwide.
SERVICES & PRODUCTS
“Going the extra mile is a big part of our DNA. Personal attention can go a long way in ensuring the success of your next research study.”
Raffaella Hart, MS, CIP
Sr. Vice President, IRB and IBC Services
Ergomed places patients and their care partners’ needs at the core of our services. We strive to build empathetic relationships with patients and their care partners, not just during the trial but also before and after. Our team provides personalized support, aiming to alleviate the burden of study participation. Ergomed and our trusted partners are deeply committed to bringing lifesaving treatments to patients.
A successful clinical trial starts with an efficient protocol review.
With deep roots in academic research and clinical medicine, BRANY IRB is uniquely positioned to meet your cost and speed requirements. Get your clinical trial to the start line while ensuring participant health and safety.
Australia is a preferred destination for early phase trials because of simple and fast regulatory stream and lucrative R&D cash refund scheme.
Experience customized and validated flow cytometry (FCM) biomarkers and panels for your clinical research on a global scale. Learn how FCM can enhance your research and help develop the panels you need.
Gain expert guidance and connect with a global network of qualified QPPVs and LPPVs, who will ensure compliance with pharmacovigilance regulations and tailor their approach to your product launch strategy.